Do cannabinoids have a role to play in Tourette’s syndrome?

Garcia et al. ·Medwave Impact 0.3

Unclear GRADE High 1 citations

Samplek = 2 Studien

Durationunclear

ControlPlacebo

EndpointTic reduction

Blindingunklar

DesignMeta-Analyse

Key finding

It is unclear whether cannabinoids reduce tics in Tourette syndrome; they are probably associated with common side effects.

Summary

Epistemonikos SR of k=2 RCTs on cannabinoids in Tourette syndrome; GRADE evidence synthesis states: unclear whether cannabinoids reduce tics; common adverse effects likely. No numerical effect sizes reported in the abstract.

PopulationPersons with Tourette syndrome – pooled from 2 randomised trials

InterventionCannabinoids (various)

ControlPlacebo

OutcomeUnclear whether cannabinoids reduce tics; common adverse effects likely

Confidence in the evidence

High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile

Sample size ★★★★★

Blinding —

Effect size —

Citations / year ★★★★★

Authors

Garcia K, Rada G

DOI 10.5867/medwave.2016.6793↗

Design: Meta-Analyse

Abstract

It has been suggested that the use of cannabinoids might play a role in the treatment of Tourettes syndrome, but there is no consensus. Searching in Epistemonikos database, which is maintained by screening multiple databases, we identified seven systematic reviews including two randomized trials addressing the question of this article. We extracted data, combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded it is not clear whether cannabinoids reduce tics in Tourettes syndrome, and they are probably associated to frequent adverse effects.

The impediment to action advances action. — Marcus Aurelius